PAPD5 Inhibitor Restores Telomerase Activity in TERC Processing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for telomere diseases such as dyskeratosis congenita and idiopathic pulmonary fibrosis are limited, with no effective medical treatments available for telomere-related disorders, particularly those caused by telomerase dysfunction.

Innovation Solution

The use of a pharmaceutical composition comprising a PAP Associated Domain Containing 5 (PAPD5) inhibitor, specifically designed as an inhibitory nucleic acid to target and inhibit PAPD5, which disrupts the degradation pathway of Telomerase RNA Component (TERC), thereby restoring telomerase activity and elongating telomeres in PARN-mutant patient cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PARN enzyme is present and active, then TERC RNA is properly processed, but in PARN-mutant cells TERC accumulates in degraded oligo-adenylated forms leading to telomerase deficiency

Engineering Contradiction:

ImproveTERC processing reliabilityVSAvoidTERC levels

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent converts the harmful accumulation of oligo-adenylated TERC forms into a beneficial outcome by using PAPD5 inhibition to prevent the harmful polyadenylation process. By blocking PAPD5, the degraded TERC forms are prevented from forming, and the harmful oligo-adenylated accumulation is converted into proper TERC processing and stabilization, thereby restoring telomerase activity in PARN-mutant cells.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces PAPD5 inhibitor as an intermediary molecule that mediates between the PARN mutation defect and the TERC processing pathway. The inhibitor acts as a compensatory mediator that blocks the alternative polyadenylation pathway (PAPD5) which would otherwise lead to TERC degradation, thereby restoring balance to the TERC processing system without directly addressing the PARN mutation.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If PAPD5 is active, then alternative polyadenylation occurs on TERC, but this leads to TERC degradation and reduced telomerase activity

Engineering Contradiction:

ImprovePolyadenylation pathway flexibilityVSAvoidTelomerase activity

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent extracts or removes the harmful alternative polyadenylation pathway mediated by PAPD5 from the TERC processing system. By specifically inhibiting PAPD5, the patent separates the harmful alternative polyadenylation route from the necessary TERC processing pathway, allowing only the beneficial canonical polyadenylation to proceed and thereby restoring reliable telomerase activity.

Inventive Principle:

Principle #2Taking out (Extraction)

3Adaptability or versatility

If no effective therapy is available for telomere diseases, then treatment options are limited, but new therapeutic approaches are needed to address telomerase dysfunction

Engineering Contradiction:

ImproveTherapeutic approach diversityVSAvoidTreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter from directly targeting PARN (which is mutated and non-functional) to targeting PAPD5 (an upstream regulator). By changing the target parameter from the defective enzyme to its regulatory partner, the patent creates a new therapeutic approach that indirectly corrects the TERC processing defect, thereby improving treatment effectiveness for telomere diseases.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively increases TERC levels and telomerase activity, addressing the telomere dysfunction and elongation defects in patient cells, providing a potential therapeutic solution for telomere-related disorders.

Implementation Method 1

administering to the subject an effective amount of the pharmaceutical composition comprising a PAP Associated Domain Containing 5 (PAPD5) inhibitor, wherein the PAPD5 inhibitor is an inhibitory nucleic acid designed to inhibit a target RNA acid

Methodology Applied

Scientific EffectNucleic acid inhibition:

Implementation Method 2

disrupts the degradation pathway of Telomerase RNA Component (TERC), thereby restoring telomerase activity

Methodology Applied

Scientific EffectRNA stabilization:

Implementation Method 3

restoring telomerase activity and elongating telomeres in PARN-mutant patient cells

Methodology Applied

Scientific EffectTelomerase-mediated telomere elongation:

Data Source

PatentEP3364974B1Modulators of telomere disease

Publication Date: 2022.07.13 CHILDRENS MEDICAL CENT CORP

Figure 1A~1B
Figure 1C~1F
Figure 2A~2C

AI summary

The disclosure relates to treating and diagnosing telomere diseases, and methods of screening agents for treating and diagnosing telomere diseases.